Related Experiment Video
Updated: Aug 12, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Two advances in the management of Parkinson disease
1Center for Functional and Restorative Neuroscience, Department of Neurology, The Cleveland Clinic Foundation, Ohio 44195, USA.
Abstract:
Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy
Antianxiety Medications
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

